GlobalData on MSN21h
Nektar Therapeutics to sell Alabama facility to Ampersand
The transaction includes $70m in cash and a $20m retained equity position for Nektar in a new Ampersand portfolio company.
FiercePharma1d
Nektar pads wallet with $90M manufacturing plant sale to Ampersand
After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...
Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential
Piper Sandler has initiated coverage on Nektar Therapeutics Inc (NASDAQ:NKTR), citing the company’s lead asset ...
Nektar To Sell Manufacturing Facility In Alabama, Reagent Supply Business To Ampersand
(RTTNews) - Nektar Therapeutics (NKTR), Monday announced a decision to sell its Alabama-based commercial-scale manufacturing facility and PEGylation reagent supply business to Ampersand Capital ...
Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama
Nektar Therapeutics (Nasdaq: NKTR), a global biotechnology company focused on the discovery and development of novel therapies to treat autoimmune disorders, today announced that it has entered into a ...
bovnews15d
Uncover the Reason: Why Nektar Therapeutics (NKTR) Stock Is Trading 241.74% Above Its 52-Week Low?
On Friday, Nektar Therapeutics (NKTR) stock saw a decline, ending the day at $1.41 which represents a decrease of $-0.04 or -2.76% from the prior close of $1.45. The stock opened at $1.44 and touched ...
Nektar Therapeutics Sells Manufacturing Facility for $90M
The latest update is out from Nektar Therapeutics ( (NKTR) ).
ETF Daily News3d
Nektar Therapeutics (NASDAQ:NKTR) Receives $2.33 Average Price Target from Analysts
Nektar Therapeutics had a negative net margin of 190.09% and a negative return on equity of 133.64%. During the same quarter in the prior year, the firm earned ($0.27) earnings per share.
Benzinga.com1d
Nektar Therapeutics (NASDAQ:NKTR) Stock, Short Interest Report
Short interest in Nektar Therapeutics (NASDAQ:NKTR) decreased during the last reporting period, falling from 7.76M to 7.31M. This put 5.08% of the company's publicly available shares short.
Stockhouse8d
Nektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases
It is wholly-owned by Nektar Therapeutics. This press release contains forward-looking statements which can be identified by words such as: "will," "can," "expect," "develop," "potential," ...